- Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: a pilot study. Urakami, S., Yoshino, T., Kikuno, N., Imai, S., Honda, S., Yoneda, T., Kishi, H., Shigeno, K., Shiina, H., Igawa, M. Urology (2005)